Ear, nose, and throat
Office-based surgery
For sinus surgeons
The precision of the operating room now in your office
Patients benefit from shorter waiting times before the procedures as well as shorter recovery times. Most patients can leave the office after being observed for 10-20 minutes after completion of the procedure.1
Shorter recovery times can be attributed to the reduced likelihood of postoperative nausea and vomiting because of the avoidance of sedatives and general anesthetics. For surgeons, incorporating procedures into their office schedule allows them to save the time associated with operating room turnover and anesthesia time.1
Sinus surgery is changing.
Basic sinus procedures are increasingly being performed in the office. Some office-based procedures can provide economic value to you and your patients.2 Medtronic is the leader in providing innovative and comprehensive ENT solutions for the office. We offer cutting-edge therapies3 and technologies designed with you and your patients in mind. Transform your office by:
- Bringing OR technology to your office procedure rooms
- Providing additional navigated treatment options
- Working with our teams to increase your comfort level with in-office therapies and procedures
- Providing in-office and digital patient education content to use in your practice
Get the office-based rhinologic surgery e-book.
StealthStation FlexENT™ navigation system
NuVent™ balloon sinus dilation system
Integrated power console (IPC™ system)
Steroid-eluting sinus implants
PROPEL™ mometasone furoate sinus implant
SINUVA™ sinus implant
Patient education for in-office sinus procedures
Reach more patients by educating your on the sinus surgeries your office performs. Medtronic ENT offerings include:
- In-office patient education. Posters, brochures, holders, and procedure videos for your waiting room.
- Digital education. Imagery, videos, and text describing procedures and therapies, from ENT anatomy to content for your website.
- Therapy awareness programs (TAP). Educational workshops covering products and therapies in partnership with a Medtronic ENT representative.
Visiting clinician program (VCP)
Medtronic has office-based ENT professionals throughout the country who can host you for a day. These courses include observations and discussion of cases, office operation, anesthesia protocol, and best practices related to in-office ENT procedures.
Resources
Contact information
6743 Southpoint Drive N
Jacksonville, FL 32216
USA
Toll free: 800-874-5797
Telephone: 904-296-9600
Fax: 800-678-3995
Nasal and sinus procedures coding guide
Use this document to look up commonly billed codes for nasal and sinus procedures.
Products
Filter by
INDICATION
SINUVA™ sinus implant is a corticosteroid-eluting implant indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥ 18 years of age who have had ethmoid sinus surgery.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA™ sinus implant.
WARNINGS AND PRECAUTIONS
Local Nasal Adverse Reactions: Monitor nasal mucosa adjacent to the SINUVA™ sinus implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.
Glaucoma and Cataracts: Nasal steroids may result in development of glaucoma and/or cataracts. Glaucoma, cataracts, and clinically significant elevation of intraocular pressure were not observed in patients from the treatment group of one randomized controlled clinical study (N = 53) who underwent bilateral placement of SINUVA™ sinus implants. Close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids.
Immunosuppression and Risk of Infections: Persons who are using drugs that suppress the immune system, such as corticosteroids, including SINUVA™ sinus implant are more susceptible to infections than healthy individuals. The safety and effectiveness of SINUVA™ sinus implant have not been established in pediatric patients less than 18 years of age and SINUVA™ is not indicated for use in this population. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
Hypercorticism and Adrenal Suppression: If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.
ADVERSE REACTIONS
The most common adverse reactions observed (> 1% of subjects) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.
POST-MARKETING EXPERIENCE
The following adverse reactions have been identified during post-approval use of the SINUVA™ sinus implant. These events include implant migration, lack of efficacy, nasal pain, headache, epistaxis.
RX only. Please see full prescribing information for the SINUVA™ sinus implant.
† Mometasone™ furoate nasal spray.
- Rao SB, Sharma CP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res 1997;34(1):21–28.
- Malette WG, Quigley H, Gaines RD, Johnson ND, Rainer G. Chitosan: a new hemostatic. Ann Thorac Surg. 1983;36:55–58.
- Chou TC, Fu E, Wu CJ, Yeh JH. Chitosan enhances platelet adhesion and aggregation. Biochem Biophys Res Commun. 2003;302:480–483.
- Kern RC, et al. Int Forum Allergy Rhinol. 2018;8:471-81